Updated results of high-dose rate brachytherapy and external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO phoenix definition

International Braz J Urol

Volumn 34, Issue 3, 2008, Pages 293-301

  Pellizon, Antonio Cassio Assis ^a,b   Salvajoli, Joao ^a   Novaes, Paulo ^a   Maia, Maria ^a   Fogaroli, Ricardo ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b NONE   (Brazil)

Author keywords

Brachytherapy; Prostate cancer; Radiotherapy; Recurrence; Treatment failure

Indexed keywords

EID: 48049117330     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/s1677-55382008000300006     Document Type: Article

References (27)

1. Smith RA, Cokkinides V, Eyre HJ: American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 2006; 56: 11-25; quiz 49-50.
2. Brasil. Ministerio da Saude. Secretaria de Atenção a Saude. Instituto Nacional do Cancer. Coordenação de Prevenção e Vigilancia. Estimativa 2006: Incência de câncer no Brasil. Rio de Janeiro, INCA. 2005; p. 39. http:/ /www.inca.gov.br/estimativa/2006/versao-final.pdf
3. Ali AS, Hamdy FC: The spectrum of prostate cancer care: from curative intent to palliation. Curr Urol Rep. 2007; 8: 245-52.
4. Khoo VS: Radiotherapeutic techniques for prostate cancer, dose escalation and brachytherapy. Clin Oncol (R Coll Radiol). 2005; 17: 560-71.
5. Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A: Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 67: 1074-81.
6. Symon Z, Griffith KA, McLaughlin PW, Sullivan M, Sandler HM: Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy. Int J Radiat Oncol Biol Phys. 2003; 57: 384-90.
7. 7. Vargas CE, Martinez AA, Boike TP, Spencer W, Goldstein N, Gustafson GS, et al.: High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. Int J Radiat Oncol Biol Phys. 2006; 66: 416-23.
8. 8. Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G: High-dose-rate intensity-modulated brachy-therapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys. 2005; 61: 1306-16.
9. 9. Pellizzon AC, Nadalin W, Salvajoli JV, Fogaroli RC, Novacs PE, Maia MA, et al.: Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Radiother Oncol. 2003; 66: 167-72.
10. Pellizzon AC, Salvajoli JV, Maia MA, Ferrigno R, Novaes PE, Fogarolli RC, et al.: Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer. J Urol. 2004; 171: 1105-8.
11. Pinkawa M, Fischedick K, Treusacher P, Asadpour B, Gagel B, Piroth MD, et al.: Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer-a phase II study. Radiother Oncol. 2006; 78: 41-6.
12. Soumarová R, Homola L, Stursa M, Perková H: Acute toxicity of conformal high dose interstitial brachytherapy boost in prostate cancer. Neoplasma. 2006; 53: 410-7.
13. Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A: A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004; 59: 380-5.
14. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al.: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965-74.
15. Phan TP, Syed AM, Puthawala A, Sharma A, Khan F: High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol. 2007; 177: 123-7; discussion 127.
16. Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, et al.: Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 58: 1048-55.
17. Deger S, Boehmer D, Roigas J, Schink T, Wernecke KD, Wiegel T, et al.: High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol. 2005; 47: 441-8.
18. Chin YS, Bullard J, Bryant L, Bownes P, Ostler P, Hoskin PJ: High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer. Clin Oncol (R Coll Radiol). 2006; 18: 474-9.
19. Yamada Y, Bhatia S, Zaider M, Cohen G, Donat M, Eastham J, et al.: Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy. 2006; 5: 157-64.
20. Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, et al.: Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys. 2005; 62: 1322-31.
21. Aström L, Pedersen D, Mercke C, Holmäng S, Johansson KA: Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol. 2005; 74: 157-61.
22. Hsu IC, Cabrera AR, Weinberg V, Speight J, Gottschalk AR, Roach M 3rd, et al.: Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer. Brachytherapy. 2005; 4: 202-6.
23. Prada Gómez PJ, de la Rua Calderón A, Romo Fonseca I, Evia Suárez M, Abascal García JM, Juan Rijo G, et al.: High dose brachytherapy (real time) in patients with intermediate- or high-risk prostate cancer: technical description and preliminary experience. Clin Transl Oncol. 2005; 7: 389-97.
24. Shigehara K, Mizokami A, Komatsu K, Koshida K, Namiki M: Four year clinical statistics of iridium-192 high dose rate brachytherapy. Int J Urol. 2006; 13: 116-21.
25. Oh RJ, Yoshioka Y, Tanaka E, Shiomi H, Sumida I, Isohashi F, et al.: High-dose-rate brachytherapy combined with long-term hormonal therapy for high-risk prostate cancer: results of a retrospective analysis. Radiat Med. 2006; 24: 58-64.
26. Chin YS, Bullard J, Bryant L, Bownes P, Ostler P, Hoskin PJ: High dose rate iridium- 192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer. Clin Oncol (R Coll Radiol). 2006; 18: 474-9.
27. Vargas CE, Demanes J, Boike TP, Barnaba MC, Skoolisariyaporn P, Schour L, et al.: Matched-pair analysis of prostate cancer patients with a high risk of positive pelvic lymph nodes treated with and without pelvic RT and high-dose radiation using high dose rate brachytherapy. Am J Clin Oncol. 2006; 29: 451-7.